PhD / Sulaiman / MD Evidence-Based Clinical Chelation

A Textbook with Protocols for the Treatment of Chronic Metal Exposure
1. Auflage 2020
ISBN: 978-3-7504-5810-9
Verlag: BoD - Books on Demand
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, 120 Seiten

This is an easy-to-read manual about chelation therapy. It contains specific protocols for the treatment of chronic metal overexposure, all of which are evidence-based, aiding the inexperienced and the experienced therapist in selecting the optimal chelating agent for the metal(s) in question. Expert chemists and chelation therapists have contributed invaluable knowledge and experience to this book. Most importantly, this is not a book promoting personal views or preferences. In fact, the information presents and explains different approaches, and allows the reader to draw his own conclusion. All the protocols listed have been modified for the treatment of chronic metal intoxication, included are oral and intravenous treatment plans. The authors explain in simple terms how a chelating agent´s bioavailability affects metal binding and how various protocols such as the Cutler Protocol affect the detoxification process, why DMPS binds mercury and which chelators are useful for the detoxification of certain organ system. Also discussed is the importance and effect of treatment pauses. Diagnostic tests are discussed, and which are useful under certain conditions. Shown are tables comparing the average metal binding ability of the various EDTAs, DMPS, DMSA and other chelating agents. Detailed information explains which chelator binds which metal and why, all of which aids the therapist in finding optimal treatment schedules. Novel chelating agents are presented such as MIADMSA, a new oral chelator specifically designed for arsenic intoxication, or how natural Pectin may be used an alternative for gadolinium intoxication, which metals are bound by lipoic acid and why a slightly alkaline environment supports metal binding, even preventing the often-feared metal redistribution. All in all, this evidence-based chelation "cookbook" should be in medical libraries and on the bookshelf of every physician treating environmental disease.

Dr. Eleonore Blaurock-Busch MSc, PhD published several books in German, English, and other languages, including textbooks on metal toxicology and diagnostics. She is a regular contributor and columnist to various journals, published hundreds of articles in various languages around the world, including research on Autism, Cancer and Chelation. She was instrumental in environmental and laboratory research projects in metal toxicology, including epidemiological studies that evaluated the toxic burden of people of various countries, including Nigeria, India and Egypt. She organized and participated as keynote speaker in international meetings, received the IBCMT (International Board of Clinical Metal Toxicology) Award for Outstanding Service in 2005, has lectured worldwide at various universities and learning institutions, and was a guest speaker at radio and TV shows in the US, Germany and elsewhere. She is a member of the British Society for Ecological Medicine and the European Academy for Environmental Medicine.

Autoren/Hrsg.

Blaurock-Busch

Flora

PhD,

Sulaiman, Md

MD,

Leseproben

Preface This book does not replace previously published books on chelation therapy by this or other authors. It is a brief and updated ‘cookbook of chelation therapy’, listing chelating agents with the potential to alleviate chronic metal intoxication. The information provided is based on present evidence. Antidote treatments of chronic overexposure are relatively new. The treatment methods described in this book are the outcome of antidote usage that focused on acute intoxications only. Due to the increasing awareness of environmental problems, a modulated treatment approach became necessary, one that is considerably less aggressive, yet still effective. Such protocols as listed here are aimed specifically at chronic overexposures rather than acute intoxications. There is one main difference between an acute intoxication and a chronic overexposure. An acute intoxication often is a life-threatening event that necessitates an aggressive medical approach; a chronically overexposed patient rarely requests such measures. Generally, an acute intoxication happens suddenly; a chronic overexposure happens over time. This also means that an acute poisoning immediately overwhelms the body’s defense mechanism, but in the case of a chronic intoxication the body has had time to adjust. Symptoms developed over time. Another, most distinct difference is that symptoms of acute intoxications are usually easily identified, whereas chronic overexposure symptoms are mostly vague and thus are difficult to identify. Furthermore, chronic ailments are often multicausal. Today’s environmentally challenged patient shows multiply burden. The diagnosis may identify insignificant exposures to numerous toxins and this accumulation of minor amounts to multiple toxins results in a respectable burden, which overwhelms enzyme systems and other vital bodily functions. Chronic disease follows in time. By reducing a chronic burden, we reduce or eliminate related symptoms. Another difference in the treatment approach of acute poisonings vs chronic overexposures is the element of time. When treating an acute case of poisoning, we are rushed to prevent acute damages, even death; when treating overexposures, we have time to dismantle the hill of toxic garbage that has piled up over time. When we improve the bodily environment, we improve health. Since 1984, I have actively worked in metal toxicology, commonly referred to as chelation. Throughout this book, I refer to detoxification therapies as ‘chelation’ as this is the name widely used and recognized for metal detoxification procedures. How did chelation therapy develop? In the Seventies and Eighties, a group of medical physicians, many of them cardiologists, were determined to set new standards and guidelines for the treatment of atherosclerotic and vascular disease. These dedicated minds set out to change medicine’s surgical approach in cardiology and eventually branched out into what is now called chelation therapy. Despite opposition from conventional cardiologists, these ‘chelation doctors’ founded organizations and achieved recognition for a treatment method they deeply believed in. I have met prominent pioneers of chelation therapy, spoke and corresponded with notable doctors and initiators of ‘alternative medicine’. I like to mention Dr. James Frackelton of Ohio, Illinois, Dr. James Puckette Carter of Lousiana (both deceased), and Dr. Peter van der Schaar of Leende, Netherlands, all founders of organizations that stood up for chelation and other ‘alternative’ medical practices. Their teachings remain, but an increase in knowledge due to research necessitates updates. Hence this book. In Germany, chelation has long been part of medicine. Due to chemical warfare threats of WWI and WWII, antidotes like BAL and DMPS were developed in England and Russia. Na2EDTA has a history of being used in German industries for its calcium-binding ability, which explains why the term ‘chelation’ has long been familiar to European and Russian industries and in medicine, long before ‘chelation therapy’ was propagated in the US and other countries. Yet American physicians like Dr. Elmer Cranton MD who had served as Chief-of-Staff at a U.S. Public Health Service Hospital in Oklahoma, turned EDTA-Chelation into an alternative treatment method for cardiac disease. Other pioneers such as Michael B Schachter MD of New York and Terry Chappel MD of Ohio are still active notables along with Dr. Ephraim Olszewer of Sao Paulo, Brazil, and the study he conducted and published 1990 in cooperation with FC Sabbaq and JP Carter was one of the first important research papers published. This widely recognized study, a pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease, was one of the first providing evidence to the usefulness of MgEDTA. (Olszewer 1990) During that time, the ACAM movement focused on NaMgEDTA chelation. Calcium i.e. plaque removal was its aim. In Germany, environmental physicians focused on mercury and the amalgam movement, thus relying on DMPS, and from 2000 on chelation groups organized in various countries around the world. Established chelation protocols were adjusted for the treatment of chronic overexposures. Articles and books were written, and a growing number of physicians became interested in chelation therapy. In the years since, official protocols involving antidotes such as DMSA, DMPS, the EDTAs, DTPAs and others were repeatedly modified for the treatment of chronic metal exposure. New research information created awareness. The main aim of this book is to help physicians understand why and how chronic and acute intoxications require different approaches, and to provide appropriate protocols for patient safety. It has not been pointed out enough that treatment approaches concerning metal overexposure vary from country to country. The access to antidotes or chelating agents varies from country to country. Antidotes or chelating agents are pharmaceuticals. These prescription items are often sold over the internet. Web pages provide user information, but are not necessarily appropriate or accurate. For instance, the difference between NaMgEDTA and NaCaEDTA is not sufficiently known and if an inexperienced therapist follows certain webpages recommendations, fatal accidents can, and have happened. This evidence-based book aims to aid patient and doctor in selecting the appropriate treatment. Furthermore, a growing number of well-intended, but not fully informed physicians use one chelation agent and protocol for detoxing one and all metals, a rather simplified approach to chelation therapy. For a patient with multiple exposures (and these are more common in today’s polluted environment), a general detox program will bring improvement. A more individualized approach provides relief much quicker. For example, if a patient suffers from a high mercury burden, DMPS or DMSA will be the chelators of choice. If the patient shows a high cadmium burden, NaCaEDTA or NaMgEDTA should be selected instead. The well-informed chelation therapist will, after the appropriate diagnosis, start to detoxify the main toxin first by selecting the most appropriate chelator. I compare chelation to the peeling of an onion. The more layers of toxins we peel, the better. Health will improve. Any chelator will remove some layer, but if we aim to remove the most critical toxin first, treatment success will come sooner. I like to point out another issue of concern. It is common today to spend less time with patients. Questionnaires are used to evaluate patient histories; few physicians have enough time to sit down and talk with patients. Dr. Ebrahim Sulaiman of Kuala Lumpur, Malaysia does take time. I met him in 2006, during IBCMT’s Malaysian conference. He impressed with medical knowledge, kindness, integrity and fondness of family, people and work. He proudly showed me his clinic. We kept in contact. When he invited me to be part of the 2nd Malaysian Conference of Metal Toxicology and Antidotes in 2019, I accepted (albeit a long travel time). During this February 2019 conference, it became clear that Dr. Sulaiman had many followers, in Malaysia and neighboring countries. New and experienced doctors interested in chelation therapy asked for an updated, comprehensive version of existing textbooks. Dr. Sulaiman had published his short book Chelation Therapy in 2001: I had published a more comprehensive version in 2016, The Chelation Therapy Handbook: Toxic Metals and Antidote. Since then, evidence-based knowledge accumulated, and thus this book was planned. Because few doctors have time to read thick volumes, we promised a ‘cookbook approach’. Over the years, MTM Laboratory of Germany accumulated and sorted through a considerable mass of data. Statistical evidence as provided in the following chapters should make physicians help select the chelator of choice. Presented here are synthetic chelators. Administering these chemicals is, in fact, a type of chemotherapy and requires knowledge and care. We must be selective in administering chelating agents. This book aims to aid physicians to provide safe and effective chelation treatments. Another issue concerns diagnostics. As chelation therapy became popular, all sorts of diagnostics devices appeared, some useful, many are not. Clever marketing of simple ‘spectrophotometric’ devices promise ‘intracellular metal results within seconds’. Cleverly designed software provides ‘test results’ that appear reasonable, however fraudulent they are. Well-meaning doctors and their trusting patients are cheated by...